Literature DB >> 16194586

Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.

C C Breathnach1, H J Clark, R C Clark, C W Olsen, H G G Townsend, D P Lunn.   

Abstract

Two novel recombinant strains of modified vaccinia Ankara (rMVA) for the vaccination of horses against equine influenza virus were developed, and preliminary evidence of their immunogenicity in ponies was demonstrated [Breathnach CC, Rudersdorf R, Lunn DP. Use of recombinant modified vaccinia Ankara vectors for equine influenza vaccination. Vet Immunol Immunopathol 2004:98;127-36]. The present study assessed the protective efficacy of these rMVA strains in ponies, examined the advantage of combining rMVA vaccination with a DNA priming dose, and investigated the protection resulting from equine influenza nucleoprotein (NP) versus haemagglutinin (HA) vaccination. Twenty yearling ponies, seronegative for equine influenza virus, were divided into four groups of five. Group 1 and Group 2 ponies were vaccinated using a DNA prime-rMVA boost vaccination regimen, with HA- or NP-expressing vectors, respectively. Group 3 ponies were vaccinated with rMVA-HA only. Group 4 ponies served as unvaccinated controls. Vaccines were administered on days 0, 42 and 70, and all ponies were challenge infected with influenza virus on day 100. Antigen-specific antibody and cellular immune responses to each vaccination regimen were monitored throughout the experiment. Both groups of HA-vaccinated ponies were significantly protected from clinical disease following challenge infection, demonstrating the efficacy of rMVA vaccination with or without a DNA prime. NP-vaccination provided more limited protection from clinical disease. The protective post-vaccinal immune responses were characterized by antigen-specific IgGa, IgGb and IgA antibodies which were induced both in serum and in nasal secretions. Virus-specific lymphoproliferative and IFN-gamma mRNA responses were also elicited by each vaccination regimen. These data demonstrate that vaccination of horses with rMVA alone, or as part of a prime-boost regimen, is an effective means of inducing protective immunity to influenza virus infection, and also indicate that NP-specific immune responses can contribute to protection of horses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16194586     DOI: 10.1016/j.vaccine.2005.08.091

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Authors:  Saravana K Kanagavelu; Victoria Snarsky; James M Termini; Sachin Gupta; Suzanne Barzee; Jacqueline A Wright; Wasif N Khan; Richard S Kornbluth; Geoffrey W Stone
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies.

Authors:  Alida Ault; Alyse M Zajac; Wing-Pui Kong; J Patrick Gorres; Michael Royals; Chih-Jen Wei; Saran Bao; Zhi-yong Yang; Stephanie E Reedy; Tracy L Sturgill; Allen E Page; Jennifer Donofrio-Newman; Amanda A Adams; Udeni B R Balasuriya; David W Horohov; Thomas M Chambers; Gary J Nabel; Srinivas S Rao
Journal:  Vaccine       Date:  2012-03-23       Impact factor: 3.641

3.  Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus.

Authors:  C R Baskin; H Bielefeldt-Ohmann; A García-Sastre; T M Tumpey; N Van Hoeven; V S Carter; M J Thomas; S Proll; A Solórzano; R Billharz; J L Fornek; S Thomas; C-H Chen; E A Clark; Kaja Murali-Krishna; M G Katze
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

4.  Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route.

Authors:  R H Mealey; D M Stone; M T Hines; D C Alperin; M H Littke; S R Leib; S E Leach; S A Hines
Journal:  Vaccine       Date:  2007-08-15       Impact factor: 3.641

5.  Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen.

Authors:  Robert H Mealey; Steven R Leib; Matt H Littke; Bettina Wagner; David W Horohov; Travis C McGuire
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

6.  Regulation of Immunogen Processing: Signal Sequences and Their Application for the New Generation of DNA-Vaccines.

Authors:  E S Starodubova; M G Isaguliants; V L Karpov
Journal:  Acta Naturae       Date:  2010-04       Impact factor: 1.845

7.  Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).

Authors:  Rachael Chiam; Emma Sharp; Sushila Maan; Shujing Rao; Peter Mertens; Barbara Blacklaws; Nick Davis-Poynter; James Wood; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240

8.  In vitro analysis of expression vectors for DNA vaccination of horses: the effect of a Kozak sequence.

Authors:  Gudbjörg Olafsdóttir; Vilhjálmur Svansson; Sigurdur Ingvarsson; Eliane Marti; Sigurbjörg Torsteinsdóttir
Journal:  Acta Vet Scand       Date:  2008-11-04       Impact factor: 1.695

9.  Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.

Authors:  Kelsey R Florek; Jason T Weinfurter; Sinthujan Jegaskanda; Joseph N Brewoo; Tim D Powell; Ginger R Young; Subash C Das; Masato Hatta; Karl W Broman; Olav Hungnes; Susanne G Dudman; Yoshihiro Kawaoka; Stephen J Kent; Dan T Stinchcomb; Jorge E Osorio; Thomas C Friedrich
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

10.  Engineering of Recombinant Sheep Pox Viruses Expressing Foreign Antigens.

Authors:  Olga Chervyakova; Elmira Tailakova; Nurlan Kozhabergenov; Sandugash Sadikaliyeva; Kulyaisan Sultankulova; Kunsulu Zakarya; Rinat A Maksyutov; Vitaliy Strochkov; Nurlan Sandybayev
Journal:  Microorganisms       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.